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Abstract
Mesothelin, a differentiation antigen present in a series of malignancies such as mesothelioma, ovarian, lung and pancreatic
cancer, has been studied as a marker for diagnosis and a target for immunotherapy. We, however, were interested in
evaluating the effects of direct targeting of Mesothelin on the viability of cancer cells as the first step towards developing a
novel therapeutic strategy. We report here that gene specific silencing for Mesothelin by distinct methods (siRNA and
microRNA) decreased viability of cancer cells from different origins such as mesothelioma (H2373), ovarian cancer (Skov3
and Ovcar-5) and pancreatic cancer (Miapaca2 and Panc-1). Additionally, the invasiveness of cancer cells was also
significantly decreased upon such treatment. We then investigated pro-oncogenic signaling characteristics of cells upon
mesothelin-silencing which revealed a significant decrease in phospho-ERK1 and PI3K/AKT activity. The molecular
mechanism of reduced invasiveness was connected to the reduced expression of b-Catenin, an important marker of EMT
(epithelial-mesenchymal transition). Ero1, a protein involved in clearing unfolded proteins and a member of the ER-Stress
(endoplasmic reticulum-stress) pathway was also markedly reduced. Furthermore, Mesothelin silencing caused a significant
increase in fraction of cancer cells in S-phase. In next step, treatment of ovarian cancer cells (OVca429) with a lentivirus
expressing anti-mesothelin microRNA resulted in significant loss of viability, invasiveness, and morphological alterations.
Therefore, we propose the inhibition of Mesothelin as a potential novel strategy for targeting human malignancies.
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Introduction
Mesothelin (MSLN), a plasma membrane differentiation
antigen, is expressed at significantly high levels in several human
cancers, including nearly all mesotheliomas [1] and pancreatic
adenocarcinomas [2,3] as wells as about 70% of ovarian cancers
[4,5] and 50% of lung adenocarcinomas [6,7]. MSLN is detected
in over 70% of fine needle aspirates (FNA) of pancreatic
adenocarcinomas [2]. Another recent study showed pleural
effusion MSLN as a useful marker for detection of malignant
pleural mesothelioma [8]. MSLN is also expressed in trace
amounts in normal mesothelial cells. MSLN gene encodes a 69-
kDa polypeptide containing hydrophobic sequence at the carboxyl
end which is removed and replaced by phosphatidylinositol.
MSLN gene contains 17 exons on human chromosome 16p13.3
and the MSLN cDNA is 2138-bp long, with an open reading
frame of 1884 base pair.
Mutant mice with inactivation of both copies of MSLN gene
were generated with the purpose of studying the function of this
protein although no detectable abnormalities were reported for
this phenotype [9] http://clincancerres.aacrjournals.org/cgi/
content/full/10/12/3937 - B8#B8. Another set of studies have
introduced MSLN to be involved in adhesion since NIH3T3 cells
transfected with a MSLN expression vector were more difficult to
remove from the culture dishes than non-transfected cells [1]. The
possibility of a role for MSLN in adhesion is supported by a study
showing that MSLN binds to CA125(MUC16), a member of the
mucin family glycoproteins, and that such interaction mediates cell
adhesion [4]. Based on these findings, the authors suggested that
there may be an important role for CA125 and MSLN in the
metastatic spread of cancer [4]. Also, mesothelin interaction with
MUC16 was suggested to facilitate peritoneal metastasis [10].
In models such as ovarian cancer, analyses of correlation
between MSLN expression, pathological variability and clinical
outcomes indicated that high MSLN expression was positively
associated with chemo-resistance in epithelial ovarian carcinoma
patients and short patient survival time [12]. MSLN and another
marker HE4 have been recently studied for their value as markers
for detection of ovarian carcinoma [5,11]. From other malignan-
cies the homologous to MSLN gene, namely Erc was found to be
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2over-expressed in rat renal carcinoma [12,13]. In gastric cancer
patients, the MSLN positive group had significantly more nodal
involvement and significantly deeper tumor invasion than the
MSLN negative group [14]. Interestingly, the 5-year survival rate
was found to be higher in MSLN positive group in this study.
Several studies have indicated important interactions between
signaling pathways involved in development of malignant
phenotype and MSLN. For example, MSLN was found to induce
expression of matrix metalloproteinases 7 (MMP-7) [15] or to
enhance expression levels of interleukin 6 (IL-6) [16]. Expression
of mesothelin is also claimed to confer resistance to apoptosis in
response to tumor necrosis factor alpha (TNF-alpha) [17]. The
MSLN gene is differentially regulated by members of the Wnt
signal transduction pathway [18]. Also, in C57MG mouse
mammary epithelial cells, MSLN was up-regulated by Wnt-1.
Interestingly, tumors with constitutive activation of the Wnt
signaling pathway, such as ovarian and pancreatic cancers, have
high MSLN expression. Additional studies are needed to fully
define MSLN function as well as the role of MSLN in
carcinogenesis. The very limited distribution of MSLN on normal
tissues portrays MSLN a suitable candidate for tumor-specific
therapy. Although strategies such as using monoclonal antibodies
targeted against MSLN have been tried before
[19,20,21,22,23,24], the effect of direct inhibition of MSLN on
the viability of cancer cells remains to be investigated. In addition
to the translational ramifications of such investigations, the
information obtained is useful for evaluating the role of MSLN
in cancer biology. In this work, we studied the effects of silencing
MSLN on viability, invasiveness and cell signaling pathways in
cancer cells derived from mesothelioma, pancreatic and ovarian
cancer. Furthermore, silencing MSLN by a lentivirus expressing
anti-mesothelin microRNA (miRNA) was also found to signifi-
cantly reduce the viability and invasiveness of ovarian cancer cells.
We have also investigated the outcome of silencing MSLN on cell
signaling characteristics of cancer cells and cell cycle progression in
order to further understand the pathways involved in the
biological role of this antigen.
Materials and Methods
Cell Lines and chemicals
Bxpc3, H2373, Ovcar5, and Skov3 cells (all obtained from the
American tissue culture collection, www.atcc.gov other than
H2373 which was obtained from national cancer institute, NCI)
were cultured in RPMI-1640 medium that was supplemented with
10% fetal bovine serum (FBS) (Sigma, St Louis, MO). Ovcar3 is
cultured in RPMI-1640 with 10% FBS with addition of 2 mM L-
glutamine and 10 mg/ml insulin. NIH3T3, Panc1, Maipaca2
(from ATCC), and OVca429 cells [25] were cultured in
Dulbecco’s Modification of Eagle’s Medium (DMEM) (Sigma)
supplemented with 10% FBS. Huvec cells were cultured in F-12K
Medium supplemented with 0.1 mg/ml heparin, 0.05 mg/ml
endothelial cell growth supplement, and 10% FBS. HT1080 cells
were cultured in MEME supplemented with 10% FBS. The above
mediums were supplemented with penicillin (100 IU/ml) and
streptomycin (100 mg/ml) (Sigma). 293FT cells were cultured in
DMEM (high glucose) supplemented with 10% FBS, 0.1 mM
MEM non-essential amino acid, 1 mM L-glutamine, and 1 mM
MEM sodium pyruvate. HT1080, NIH3T3, and Huvec cells were
purchased from ATCC (Manassas, VA). 297FT cells were
purchased from Invitrogen (Carlsbad, CA).
Anti-mesothelin siRNA was ordered from Qiagen (Valencia,
CA). It was synthesized in double-stranded format with Alexa
Fluor 488(AF488) conjugated to the 39 end of its sense strand. The
siRNA oligo was re-suspended in the provided buffer at final stock
concentration of 20 mM.
SiRNA electroporation
10
7 to 5610
7 cells were re-suspended in 270 ml of Opti-MEM
and mixed with 30 mlo f2 0 mM siRNA stock solution and
electroporated (,240 V, one pulse for 20 milliseconds), so the final
concentration of anti-mesothelin siRNA was 2 mM. The brightest
cells, i.e., the cells with the most amount of siRNA, were selected
on the basis of the presence of Alexa Fluor 488 tag at the 39 end of
siRNA molecule using FACS.
Cell proliferation assay
Cell proliferation assay was performed using WST-1 kit from
Millipore (Billerica, MA) according to the manufacturer’s protocol.
Briefly, 2,000 cells (sorted by FACS) were plated in each well of a
96-well microplate in a final volume of 100 ml. Then 10 ml/well of
WST-1 reagent was added and the plate was incubated for 1 hour
in standard culture conditions. During incubation, viable cells
convert WST-1 reagent into formazan dye by cellular mitochon-
drial dehydrogenase. Following this incubation, the absorbance
was measured at 440/600 nm.
Cell invasion assay
The matrigel invasion chambers and falcon companion tissue
culture plate were obtained from BD Biosciences (San Jose, CA).
For siRNA experiments control and anti-mesothelin siRNA-
treated cells (30,000 cells/well) were plated in 24-well plate and
incubated at 37uC with 5% CO2. Forty-eight hours later, the cells
were fixed in 100% methanol and stained in 0.05% crystal violet
and photographed to visually count the number of invaded cells.
For lentivirus related experiments cells were pre-treated with
lentivirus for 3 days and then introduced to the Boyden chamber
assay for ,21 hrs.
Western blot analysis
Cells were lysed at 5, 24, and 48 hours post-electroporation
with 16 cell lysis buffer. Thirty microgram of proteins for each
sample was loaded onto 4–20% SDS polyacrylamide gel (Bio-Rad,
CA). Proteins were then transferred onto a nitrocellulose
membrane. The membrane was blocked, washed, and incubated
with the different primary antibodies such as mesothelin (Abcam,
MA and LS Bio, WA) and b-actin (Cell Signaling Technology,
MA), followed by the HRP-conjugated secondary antibody. After
a thorough washing, the blot was exposed to ECL (GE Healthcare,
NJ) and autoradiography.
Cell cycle assay
Cell cycle assay was performed according to manufacturer’s
instructions. Briefly, about 10
6 cells were washed twice using
CycleTEST PLUS Buffer solution (BD Biosciences, Cat. 340242).
Cells were re-suspended in 1 ml of the same buffer. To stain the
cells, 250 ml of Solution A and 200 ml Solution B were added and
incubated for 10 minutes at RT. Cold Solution C (200 ml) was
added and incubated at 4uC for 10 minutes. The cells were filtered
through a 35 mm cell strainer and analyzed by FACSort flow
cytometer.
Construction of vector expressing miRNA
We designed and synthesized three miRNA mimics targeting
the full length of human mesothelin gene (gene access number:
NM_005823.4). Each designed miRNA mimic was 64 nucleotides
in length, including partial flanking sequence, the miRNA hairpin,
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gene as follows: 1-TGCTGATAGCAGCAGGTCCAATGGGAGTT-
TTGGCCACTGACTGACTCCCATT GCCTGCTGCTAT; 2-
TGCTGTTCATGTTCTGGAAAGCAAGGGTTTTGGCCACTG-
ACTGACCCTTGCT TCAGAACATGAA; and 3-TGCTG-
TTTACTGAGCGCGAGTTCTCTGTTTTGGCCACTGACTGA-
CAGAGA ACTCGCTCAGTAAA.
Using the BLOCK-iT Pol II miR RNAi expression vector kit
(Invitrogen, CA), we annealed and cloned the oligos encoding the
engineered pre-miRNA into the cloning site (ACGA and CAGG)
of pcDNA 6.2-GW/EmGFP-miR vectors that is flanked on either
side to allow directional cloning or proper process of pre-miRNA.
The pre-miRNA was inserted into the 39-UTR of EmGFP gene-
driven by Pol II promoters. EmGFP allows tracking expression of
the miRNA, providing a strong correlation between EmGFP and
miRNA expression. Each plasmid was sequenced to confirm the
inserted double stranded miRNA oligos. The expressing plasmids
were electroporated into Ovcar5 cells or Skov3 cells, and analyzed
by FACS to ensure the proper expression of miRNA in ovarian
cancer cells.
Generation of lentiviral particles expressing miRNA
The entry clone was generated by combining pMSLNmiR3
with pDONR 221 construct using BP Clonase II enzyme. The
miRNA cassette was transferred into the pLenti6.3/TO/V5-
DEST vector containing attR1-attR2 sites using LR Clonase II
to create the final lentiviral vector MSLNmiR3. In addition,
we created a lentiviral vector encoding scrambled miRNA
(Negative Control) (TGCTGAAATGTACTGCGCGTGGAGA-
CCTTTTGGCCACTGACTGACGTCTCCAC GCGCAGTA-
CATTT) (Invitrogen) that does not target any known human gene.
The expression of miRNA is driven by CMV promoter. The
inserted sequences of miR3 and scrambled miRNA were
confirmed by sequence analysis.
Production, titration and infection of lentiviral particles
The MSLNmiR3 or Negative Control lentivirus was transfected
with ViraPower packing mix (Invitrogen, CA) into human 293FT
cells using Lipofectamine 2000 in Opti-MEM I medium (Invitro-
gen, CA) and cultured overnight. The cells were placed under
blasticidin (10 mg/ml) selection for 72 hours. The supernatant was
collected and lentiviral particles were concentrated using Lenti-X
Concentrator (Clontech, CA). Lentiviral stock was diluted in ten-
fold serial to infect the HT1080 cells. Forty-eight hours post-
infection, the cells were assessed by FACS and the titration was
calculated using the formula [FxC/V]xD, where ‘‘F’’ is the
frequency of GFP-positive cells; ‘‘C’’ is the total number of cells in
the well at the time of transduction; ‘‘V’’ is the volume of
inoculums in mL; and ‘‘D’’ is lentivirus dilution. Ovca429 cells
were infected with lentivirus particles at MOI,30 in the presence
of polybrene (10 mg/ml) overnight. The cell proliferation assay was
performed post-infection at the indicated time points.
Flow cytometry
Cultured cells were dissociated with cell dissociation buffer
(Sigma-Aldrich, MO) and washed twice in MACS buffer (PBS plus
EDTA and 0.5% bovine serum albumin) (Miltenyi Biotec, CA). A
total of 2610
5 cells (100 ml) were incubated with mesothelin
monoclonal antibody (final concentration, 1 mg/ml) (Cat#ab3362,
Abcam, MA) on ice for 1 hour in the darkness. Cells were then
washed twice with MACS buffer, re-suspended in 100 mlo fa
secondary antibody (1:200 dilution, APC conjugated IgG; BD
Biosciences, NJ), and incubated on ice for 1 hour in the darkness.
Cells were washed twice and analyzed on LSRII analyzer (BD
Biosciences, NJ) using the software FACS Diva version 6.1. Cells
stained with secondary antibody alone were included to prove the
specificity of antibody.
Results and Discussion
We decided to evaluate the effects of silencing MSLN by using
short-interfering RNA (siRNA). Mechanistically, these 19–21
oligomers can bind to a specific matching sequence in their target
messenger RNAs (mRNAs) and flag them for destruction by a
complex referred to as RNA-induced silencing complex (RISC).
To achieve this, the sequence of MSLN mRNA was analyzed with
specialized software (Qiagen, CA) and sequences for siRNA
oligomers were detected. One of these sequences (59-
CTGGACGTCCTAAAGCATAAA-39) was selected because of
its higher degree of specificity against MSLN. The anti-MSLN
siRNA oligomer was synthesized (in double-stranded format) and
conjugated to Alexa Fluor 488 at the 39-end of its sense strand
(Qiagen, CA). Figure 1A shows the mRNA sequence for human
MSLN and the binding site for anti-MSLN siRNA.
In order to investigate the effects of anti-MSLN siRNA on the
expression of MSLN, we used the H2373 human mesothelioma
cell line. As shown in figure 1B, once electroporated with the anti-
MSLN siRNA, the expression of MSLN was notably reduced as
early as 24–48 hours post-electroporation as compared with the
negative control treated cells. No changes were observed in the
expression of b-actin (a house-keeping gene product) after
exposure of cells to the anti-MSLN siRNA (figure 1C).
We then decided to test the proliferation rate of cancer cells in
such conditions. As is seen in figure 1D, a significant reduction
(p,0.005) in the proliferation of mesothelioma cells was observed
as early as 48 hours post-electroporation. It is important to note
that proliferation rate of control siRNA-treated cells at each time-
point was measured and then scaled as 100%. The proliferation
rate of anti-MSLN siRNA treated cells was calculated and scaled
as a fraction of the control values. The callout panels represent the
cell density of the test and control treated populations at indicated
times post-electroporation. Interestingly the proliferation rate of
siRNA-treated cells started to increase at 72–96 hours post-
electroporation. This is due to the transient nature of transfection
by electroporation which is the method used in these experiments
to introduce anti-MSLN siRNA to cells. In other words, as the
time passes, the concentration of siRNA in treated cells would
diminish allowing a rebound of proliferation. We have observed
such phenomenon in our other studies involving gene specific
silencing [26,27]. Once the same procedure was applied to
NIH3T3 cells (void of MSLN), no statistically significant changes
in the viability was observed (the siRNA used in this experiment
can bind to mouse MSLN mRNA) (figure 1E).
In next step, we decided to test the effects of silencing MSLN in
other MSLN-expressing cells including ovarian and pancreatic
cancer cell lines and compare such effects with our data about
mesothelioma cells. The levels of expression of MSLN in a panel of
pancreatic and ovarian cancer cells were tested using western
blotting as shown in figure 2A. Miapaca2, BxpC3 and Panc1
(pancreatic cancer cell lines) and Skov3 and Ovcar3 (ovarian
cancer cell lines) showed increased levels of MSLN expression
while Huvec (Human umbilical vein endothelial cells) and
NIH3T3 cells remained negative for MSLN as expected.
Electroporation of all above mentioned cancer cell lines resulted
in a significant reduction in their viability (figure 2B–2D, results
shown for Skov3, BxPC3 and MiapaCa2). Once again a rebound
of proliferation due to clearance of siRNA from pancreatic and
ovarian cancer cells was observed. The time frame for this
Targeting Mesothelin for Cancer Therapy
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clearance rate of siRNA.
While all cancer cells showed significant loss of viability upon
electroporation with anti-MSLN siRNA, cells with no expression
of MSLN such as NIH3T3 did not exhibit significant changes in
their proliferation rates once electroporated with anti-MSLN
siRNA (targeting mouse MSLN). Therefore, normal cells, with
very low or no expression of MSLN would not be affected by this
strategy implying the specificity of the biological outcomes of
MSLN silencing for malignant cells. Therefore inhibition of
Figure 1. Gene specific silencing of mesothelin reduces proliferation of mesothelioma cells. (A)Anti-mesothelin siRNA was designed to a
middle sequence position in mesothelin mRNA. (B)Once electroporated with anti-mesothelin siRNA, the expression levels of mesothelin was
significantly reduced in H2373 cells. Negative control siRNA did not cause such reduction. Lower panel shows the results of band-densitometry
comparing the intensity of mesothelin expression upon electroporation of H2373 cells with siRNA. (C)Anti-mesothelin siRNA did not affect the
expression levels of b-actin, a house-keeping protein, as an evidence for the specificity of this anti-mesothelin siRNA for its target. (D) Proliferation
rate of H2373 cells is significantly (p,0.05) reduced at 48 hours post-electroporation to 40% of the values for negative control treated cells. A
rebound to higher proliferation rates is observed due to clearance of siRNA from cells at later time points in harmony with our previous studies.
Callout panels show the density of cells in each group of the study at 48 hours post-electroporation. (E) NIH3T3 cells are void of mesothelin and their
proliferation rate is not affected by exposure to anti-mesothelin siRNA (mouse). Callout panels show the density of cells at 48 hour post-
electroporation.
doi:10.1371/journal.pone.0033214.g001
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tumors such as mesothelioma, ovarian and pancreatic cancer in a
cell specific manner. Recent clinical trials using monoclonal
antibodies against MSLN have also been reported to be well-
tolerated in patients confirming minimal in-vivo side effects for
MSLN targeting strategies [28,29]. This is of special importance
due to the limited levels of mesothelin expression in pleural,
pericardial, and peritoneal membranes [30,31].
We were also interested in investigating the corollary of
silencing MSLN on the invasiveness of cancer cells. Metastasis
as the most devastating outcome of malignancies plays an
important role in the pathogenesis of cancer. Therefore, it is a
logical step to study the outcome of silencing mesothelin on the
capabilities of cancer cells to invade. This is also an important
concern considering the invasive nature of malignancies studied in
this work. For such purpose we used an in-vitro model based on
studying the capabilities of cells to invade through a layer of
matrigel as a model for metastasis (modified Boyden chamber
assay). We evaluated the invasiveness of H2373, Skov3 and BxPC3
cells once treated with anti-MSLN and control siRNA (figure 3A–
3C). In all three cases a significant reduction in invasiveness was
observed. The decreased invasiveness of all tested cancer cells is of
Figure 2. Mesothelin silencing reduces proliferation rate of pancreatic and ovarian cancer cells. (A)Mesothelin protein was detected in
pancreatic cancer cell lines, Panc1, Miapaca2 and Bxpc3 and ovarian cancer cells Skov3 and Ovcar3. NIH3T3 and Huvec cells which are void of
mesothelin were used to prove the specificity of mesothelin antibody. (B)Skov3 cells had reduced proliferation at day 3 post-electroporation with
anti-mesothelin siRNA to about 50% of negative control. Callout panels show the density of cell at each time-point. (C–D)Two pancreatic cancer cell
lines, Bxpc3 and Miapaca, were tested for the outcome of silencing mesothelin on their proliferation. In both cases a significant loss of proliferation
was observed, however for Bxpc3 the decline initiates at later time points as compared with Miapaca cells. For both cells, once again, a rebound to
higher proliferation rates is observed at longer time-points due to the clearance of siRNA from cells. Callout panels show the density of cell at each
time-point.
doi:10.1371/journal.pone.0033214.g002
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progression. (A) Once tested in a modified Boyden chamber assay, the invasiveness of H2373 mesothelioma cells is reduced significantly (p,0.05)
upon mesothelin silencing. Electroporated cells were introduced to the invasion chambers for this experiment and invaded cells were counted and
photographed after 48 hrs. Callout panels represent the density of invaded cells stained with crystal violet. (B–C) Skov3 and Bxpc3 cells both exhibita
significant (p,0.05) decrease in their invasiveness upon mesothelin silencing to values less than 20% of negative control. Callout panels represent
the density of invaded cells stained with crystal violet. (D) Silencing mesothelin induces a significant decrease in activation (phosphorylation) of ERK1
(but not ERK2) and phospho-AKT. Additionally, the expression of b-catenin, a known EMT marker, was reduced. Slug, another transcription factor
involved in EMT showed a slight increase under this condition. From ER-Stress markers, Ero-1 was decreased while Bip was slightly elevated. (E)
Progression of cell cycle is altered by mesothelin silencing mainly by an increase in the percentage of cells in S-phase. The percentage of cells in each
phase is shown in upper panel and representative flow cytometry data is offered in the lower panel. G1, S and G2 picks are marked on each graph
showing an increase in S phase population of cells.
doi:10.1371/journal.pone.0033214.g003
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diseases.
To this end, we had observed the loss of viability and
invasiveness in a range of cancer cells upon silencing of MSLN.
In order to somewhat elucidate the molecular mechanism
underlying such phenotypic changes we evaluated the activa-
tion/expression level of some of the most important signaling
proteins involved in neoplastic transformation in H2373 cells
(figure 3D). Effector pathways down-stream of proto-oncogene
Ras [32,33,34] such as activation of ERK1/2 (extracellular signal-
related kinase), phosphatidylinositol 3-kinase (PI3K/AKT) and
p38 (p38-kinase) were studied for this purpose. We observed that
upon MSLN silencing, phospho-ERK1 and phospho-AKT
activation levels were profoundly decreased while the levels of
phospho-p38 remained unchanged (figure 3D). With involvement
of ERK in proliferation and metastasis [35,36] and also
involvement of PI3K/AKT pathway in protection against
apoptosis [37], a decrease in the activation of these signaling
pathways can explain the anti-proliferative effects of silencing
MSLN. However, p38-pathway [38] (involved in stress signaling,
apoptosis and senescence) seemed to remain unaltered upon
inhibition of MSLN. Since p38-kinase acts as a growth inhibitory
pathway, it is conceivable that the capacity of cells to undergo
growth inhibition and/or apoptosis (dictated by p38-kinase
pathway) remains unaffected by silencing MSLN.
The outcome of siRNA-mediated knockdown of MSLN on
epithelial-mesenchymal transition (EMT) [39,40], a biological
program for enhancement of metastatic capabilities, was also
investigated by our team. EMT is an important biological step
towards achievement of a metastatic phenotype by cancer cells
[41]. Beta-Catenin, one of Wnt down-stream signaling molecules
and also an important player in EMT, was found to be
significantly reduced upon silencing MSLN (figure 3D, the middle
panel). Slug, another transcriptional repressor involved in EMT
was found to be somewhat increased upon MSLN silencing [42].
With considerations to the role of Slug in repression of E-Cadherin
[43] it would be a logical next step to evaluate the expression levels
of E-Cadherin upon mesothelin silencing. However, no meaning-
ful change was observed in the levels of E-Cadherin (data not
shown). Therefore the incremental increase in the levels of this
protein may not positively affect the EMT capabilities of cancer
cells once mesothelin is silenced.
We were also interested to investigate the levels of expression of
markers involved in the regulation of ER-stress. Stress situations
interrupting ER function lead to accumulation of unfolded
proteins in the ER which is referred to as ER-Stress [44,45].
Upon such conditions an integrated panel of signaling pathways
becomes activated resulting in the unfolded protein response
(UPR) [46,47]. Following continuation of the UPR response and if
the unfolded proteins are not cleared mechanism will be activated
to induce cell death. Existence of chronic ER-Stress conditions is
becoming increasingly evident in cancer cells [47]. Therefore it
would be novel and interesting to see if changes in ER-Stress
pathway would contribute to the outcome of MSLN silencing in
cancer cells.
ER-residing protein endoplasmic oxidoreductin-1 (Ero1), one of
the molecules involves in ER-stress pathway, oxidizes protein
disulfide isomerase (PDI), which, in turn, introduces disulfide
bands to ER proteins [48]. The significant decrease observed in
Ero1 upon MSLN silencing might result in a decreased capacity of
cancer cells to fold and clear proteins leading to their eventual
death (Figure 3D, lower panel). Also, an increased expression was
observed in Bip (Luminal binding protein precursor), a molecular
chaperon involved in preventing protein aggregation [49]. Such
observation might be indicative of elevated levels of protein
unfolding upon MSLN silencing as Bip levels are usually raised in
the cell to combat aggregation of unfolded proteins [50].
The last phenotypical feature studied in MSLN-silenced cells
was the progression of cell cycle. The major change observed in
these cells was a significant increase (,50%) in the fraction of cells
in S-phase portraying a blockade in progression from S to G2
phase (figure 3E).
The current approach for advancing inhibitory RNA therapy to
pre-clinical and clinical studies mainly relies on using lentiviruses
in order to express and deliver siRNA molecules in a continuous
manner [51,52,53]. For such purpose, and to produce a
translational tool for targeting cancer cells on the basis of
inhibition of MSLN, we decided to develop a lentivirus expressing
anti-MSLN miRNA. Such tool can be used in future to further
evaluate the pre-clinical value of MSLN gene specific silencing as a
therapeutic approach.
As short ribonucleic acid (RNA) molecules (,22 nucleotides)
found in all eukaryotic cells, miRNAs are post-transcriptional
regulators which bind to complementary sequences on target
mRNA transcripts. This results in translational repression and
gene specific silencing [54,55]. Once a series of three miRNA
sequences (miR1, miR2 and miR3, relative positions are shown in
figure 4A, upper panel) were selected, each of them was cloned
into an expression plasmid (pcDNA6.2-GW/EmGFP, Invitrogen)
and electroporated into Ovcar5 cells. All plasmids were efficiently
electroporated into the cells (based on GFP expression) (figure 4A,
middle panel). Two of the designed miRNAs (miR1 and miR3) out
of three silenced MSLN efficiently as was revealed by western
blotting (figure 4A, lower panel). Further, miR3 was selected to
develop the anti-MSLN lentivirus (named MSLNmiR3). The
structure of the MSLNmiR3 lentivirus is shown in figure 4B (upper
panel). Ovarian cancer cell line Ovca429 cells, with high levels of
MSLN expression, were infected by MSLNmiR3 and its negative
control counterpart (encoding scrambled sequence) at MOI,30.
The percentage of MSLN-expressing cells were reduced from
,77% in cells treated with the negative control virus to 18% in
cells treated with MSLNmiR3 (figure 4B, middle panel). For both
viruses, the viral entrance was almost equal as was proven by
EmGFP expression (figure 4B, lower panel).
In next step, we evaluated the viability of ovarian cancer cells
once treated with this virus. The viability of Ovca429 cells upon
infection with MSLNmiR3 (MOI,30) showed about 15%
decreases at day-6 post-infection and about 50%, 60% reduction
at day-16 and day-22, respectively (figure 5A). This is achieved by
treatment with a single dose of the virus. Figure 5B shows the
morphology of cells treated with MSLNmiR3 or the negative
control virus at day-16 (206 objectives) and day-6 (106
objectives). An interesting phenomenon was the enlargement of
remaining cells upon exposure to MSLNmiR3 lentivirus. This
might entail a role for MSLN in machinery involved in the cell
morphology, polarity and cytoskeletal reorganization which
influences invasiveness of cancer cells although the field needs
more studies in this regards [41,56,57]. Additionally, the
resemblance in the biological outcome of silencing mesothelin by
two distinct agents, siRNA and miRNA, reduces the possibility of
off-target events and involvement of any player other than MSLN
in this scenario. Also, the rate of loss of viability upon targeting
cancer cells with anti-mesothelin lentivirus is notably slower as
compared to silencing mesothelin by siRNA electroporation. This
is due to the kinetics of the expression of miRNA from the context
of lentiviral genome which happens at a much slower rate in
comparison to the rapid influx of siRNA to cytoplasm achieved by
siRNA electroporation.
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chamber assay also showed a close to 40% reduction in the
metastatic capability of Ovca429 cells at day-2 post-infection.
Such information reveals a significant role for mesothelin in
influencing the metastatic capability of cancer cells. The work,
therefore, provides clues to the mechanisms involved in the role of
MSLN in cancer cell’s proliferative capabilities, invasion (through
EMT marker changes), ER-Stress signaling and phenotypical
changes.
Conclusion and Future Directions
The biological function of MSLN is not well-understood. This
study delineates functional role of MSLN in cancer cell survival
and possible signaling pathways that may confer MSLN action in a
number of distinct malignancies. This is indeed of significant
importance because cancer models pursued in this report
(mesothelioma, pancreatic and ovarian cancers) seem to collec-
tively follow the outcome of elimination of MSLN as a biological
turn-point.
It is also important to take notice of the level ‘‘cancer cell
addiction’’ to the expression of this differentiation antigen for the
Figure 4. MiRs suppress MSLN expression in human ovarian cancer cells. (A) Upper panel: miRNA mimics (miR) target full length human
MSLN gene. The arrow represents the relative position of miRs across MSLN gene sequence. The exact miR sequences are explained in the
Experimental Procedure. Middle panel: Expression plasmids encoding scrambled miR or miR targeting MSLN were electroporated (voltage: 1170 V,
width: 30 ms, and pulses: 1. Neon Electroporation System, Invitrogen, CA) into human ovarian cancer Ovcar-5 cells and cultured for 48 hrs. EmGFP
expression which indicates proper orientation and expression of each miR was determined by FACS. Lower panel: MSLN protein levels were
determined by Western blot following electroporation of cells with miRs. (B) Upper panel: Schematic representation of lentiviral genome encoding
miR3 against MSLN or scrambled miR. Middle panel: Ovca429 cells were infected by lentiviral particles carrying scrambled miR (Neg. Ctrl) or miR3
against MSLN (MSLNmiR3) at MOI,30 for 3 days. Expression of MSLN was determined by FACS. The far right panel is infected with negative control
virus without staining for MSLN but stained with secondary antibody. Lower panel: The equal expression of EmGFP proves entrance and activity of
the negative control and MSLNmiR3 viruses.
doi:10.1371/journal.pone.0033214.g004
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studied cancer models show that a significant loss of viability
follows the loss of MSLN expression. In light of this, MSLN can be
rendered as suitable candidate for drug therapy with focus on
finding novel small molecule inhibitors which can bind and inhibit
MSLN. Our data in regards to cell signaling changes upon MSLN
silencing are useful for developing evaluation assays for studying
biochemical function of such anti-MSLN compounds. Once such
compounds with inhibitory function against MSLN are available,
their effect on the relationship between MSLN and CA125 can be
studied. Our team is involved in such drug discovery efforts as well
and has found a few compounds with enhanced cytotoxicity
against MSLN expressing cancer cells (unpublished data).
The other tool provided in our work, the anti-MSLN lentivirus
(MSLNmiR3), can also serve as a translational tool for the gene
therapy of MSLN expressing tumors. Animal experiments are
under way for evaluating the efficiency of this virus in causing
tumor regression in-vivo. Altogether, our findings revealed MSLN
as a potential target for achieving better understanding of the
biology of a number of human malignancies as well as designing
novel therapeutic strategies for cancer therapy.
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